Eponyms in Oncology: Bence-Jones Protein
This weekly series highlights eponyms in oncology. This week, we explore the history and namesake of the Bence-Jones protein.
This weekly series highlights eponyms in oncology. This week, we explore the history and namesake of the Bence-Jones protein.
This weekly series highlights eponyms in oncology. This week, we explore the history and namesake of Waldenström macroglobulinemia.
Patients with CLL were significantly more likely to have an antibody response to the Moderna vaccine than to the Pfizer-BioNTech vaccine.
Adding ibrutinib to rituximab improved responses and progression-free survival.
Responses improved over time, and the best overall response rate was 85%.
The FDA has accepted a supplemental new drug application (sNDA) for brukinsa for the treatment of adults with Waldenström Macroglobulinemia (WM).
Response depth appeared to be predictive of PFS in WM patients treated with ibrutinib.
A case report detailed reinfection with SARS-CoV-2 in an immunocompromised patient with Waldenström macroglobulinemia.
Among a subset of patients with previously treated Waldenström macroglobulinemia, ibrutinib is highly active and may lead to long-term disease control.
Investigators measured ixazomib, dexamethasone, and rituximab combination treatment among patients with treatment-naive Waldenström macroglobulinemia.